Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes

  • Michaeli, Orli (Division of Hematology/Oncology, The Hospital for Sick Children, University of Toronto) ;
  • Tabori, Uri (Division of Hematology/Oncology, The Hospital for Sick Children, University of Toronto)
  • Received : 2018.02.08
  • Accepted : 2018.03.08
  • Published : 2018.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Germline mutations in cancer causing genes result in high risk of developing cancer throughout life. These cancer predisposition syndromes (CPS) are especially prevalent in childhood brain tumors and impact both the patient's and other family members' survival. Knowledge of specific CPS may alter the management of the cancer, offer novel targeted therapies which may improve survival for these patients, and enables early detection of other malignancies. This review focuses on the role of CPS in pediatric high grade gliomas (PHGG), the deadliest group of childhood brain tumors. Genetic aspects and clinical features are depicted, allowing clinicians to identify and diagnose these syndromes. Challenges in the management of PHGG in the context of each CPS and the promise of innovative options of treatment and surveillance guidelines are discussed with the hope of improving outcome for individuals with these devastating syndromes.

Keywords

References

  1. Adam R, Spier I, Zhao B, Kloth M, Marquez J, Hinrichsen I, et al. : Exome sequencing identifies biallelic MSH3 germline mutations as a recessive subtype of colorectal adenomatous polyposis. Am J Hum Genet 99 : 337-351, 2016 https://doi.org/10.1016/j.ajhg.2016.06.015
  2. Albers AC, Gutmann DH : Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother 9 : 535-539, 2009 https://doi.org/10.1586/ern.09.4
  3. Amayiri N, Tabori U, Campbell B, Bakry D, Aronson M, Durno C, et al. : High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. Int J Cancer 138 : 380-385, 2016 https://doi.org/10.1002/ijc.29724
  4. de Andrade KC, Mirabello L, Stewart DR, Karlins E, Koster R, Wang M, et al. : Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history. Hum Mutat 38 : 1723-1730, 2017 https://doi.org/10.1002/humu.23320
  5. Andrianova MA, Chetan GK, Sibin MK, Mckee T, Merkler D, Narasinga RK, et al. : Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours. J Pathol 243 : 331-341, 2017 https://doi.org/10.1002/path.4957
  6. Aubrey BJ, Strasser A, Kelly GL : Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb Perspect Med 6 : a026062, 2016 https://doi.org/10.1101/cshperspect.a026062
  7. Baas AF, Gabbett M, Rimac M, Kansikas M, Raphael M, Nievelstein RAJ, et al. : Agenesis of the corpus callosum and gray matter heterotopia in three patients with constitutional mismatch repair deficiency syndrome. Eur J Hum Genet 21 : 55-61, 2013 https://doi.org/10.1038/ejhg.2012.117
  8. Bainbridge MN, Armstrong GN, Gramatges MM, Bertuch AA, Jhangiani SN, Doddapaneni H, et al. : Germline mutations in shelterin complex genes are associated with familial glioma. J Natl Cancer Inst 107 : 384, 2015
  9. Bakry D, Aronson M, Durno C, Rimawi H, Farah R, Alharbi QK, et al. : Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer 50 : 987-996, 2014 https://doi.org/10.1016/j.ejca.2013.12.005
  10. Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, et al. : Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging. JAMA Oncol 3 : 1634-1639, 2017 https://doi.org/10.1001/jamaoncol.2017.1968
  11. Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, et al. : A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 19 : 1135-1144, 2017 https://doi.org/10.1093/neuonc/now282
  12. Bleeker FE, Hopman SMJ, Merks JHM, Aalfs CM, Hennekam RC : Brain tumors and syndromes in children. Neuropediatrics 45 : 137-161, 2014 https://doi.org/10.1055/s-0034-1368116
  13. Bogler O, Su Huang HJ, Kleihues P, Cavenee WK : The p53 gene and its role in human brain tumors. Glia 15 : 308-327, 1995 https://doi.org/10.1002/glia.440150311
  14. Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, et al. : Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic. Fam Cancer, 2017 [Epub ahead of print]
  15. Bouffet E, Larouche V, Campbell BB, Merico D, De Borja R, Aronson M, et al. : Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34 : 2206-2211, 2016 https://doi.org/10.1200/JCO.2016.66.6552
  16. Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. : Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 33 : 2345-2352, 2015 https://doi.org/10.1200/JCO.2014.59.5728
  17. Brodeur GM, Nichols KE, Plon SE, Schiffman JD, Malkin D : Pediatric cancer predisposition and surveillance: an overview, and a tribute to Alfred G. Knudson Jr. Clin Cancer Res 23 : e1-e5, 2017 https://doi.org/10.1158/1078-0432.CCR-17-0702
  18. Broekman ML, Risselada R, Engelen-Lee J, Spliet WG, Verweij BH : Glioblastoma multiforme in the posterior cranial fossa in a patient with neurofibromatosis type I. Case Rep Med 2009 : 757898, 2009
  19. Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, et al. : Comprehensive analysis of hypermutation in human cancer. Cell 171 : 1042-1056.e10, 2017 https://doi.org/10.1016/j.cell.2017.09.048
  20. Cancer Genome Atlas Research Network : Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 : 1061-1068, 2008 https://doi.org/10.1038/nature07385
  21. Cruz GR, Dias Oliveira I, Moraes L, Del Giudice Paniago M, De Seixas Alves MT, Capellano AM, et al. : Analysis of KIAA1549-BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas. J Neurooncol 117 : 235-242, 2014 https://doi.org/10.1007/s11060-014-1398-1
  22. Distelmaier F, Fahsold R, Reifenberger G, Messing-Juenger M, Schaper J, Schneider DT, et al. : Fatal glioblastoma multiforme in a patient with neurofibromatosis type I: the dilemma of systematic medical follow-up. Child's Nerv Syst 23 : 343-347, 2007 https://doi.org/10.1007/s00381-006-0222-4
  23. Dodgshun AJ, Sexton-Oates A, Saffery R, Sullivan MJ : Biallelic FANCD1/BRCA2 mutations predisposing to glioblastoma multiforme with multiple oncogenic amplifications. Cancer Genet 209 : 53-56, 2016 https://doi.org/10.1016/j.cancergen.2015.11.005
  24. Dudley JC, Lin MT, Le DT, Eshleman JR : Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 22 : 813-820, 2016 https://doi.org/10.1158/1078-0432.CCR-15-1678
  25. Durno C, Boland CR, Cohen S, Dominitz JA, Giardiello FM, Johnson DA, et al. : Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology 152 : 1605-1614, 2017 https://doi.org/10.1053/j.gastro.2017.02.011
  26. Eaton KW, Tooke LS, Wainwright LM, Judkins AR, Biegel JA : Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 56 : 7-15, 2011 https://doi.org/10.1002/pbc.22831
  27. Eisenstat DD, Pollack IF, Demers A, Sapp MV, Lambert P, Weisfeld-Adams JD, et al. : Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945. J Neurooncol 121 : 573-581, 2015 https://doi.org/10.1007/s11060-014-1669-x
  28. Elmariah SB, Huse J, Mason B, Leroux P, Lustig RA : Multicentric glioblastoma multiforme in a patient with BRCA-1 invasive breast cancer. Breast J 12 : 470-474, 2006 https://doi.org/10.1111/j.1075-122X.2006.00307.x
  29. Esteban-Jurado C, Gimenez-Zaragoza D, Munoz J, Franch-Exposito S, alvarez-Barona M, Ocana T, et al. : POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget 8 : 26732-26743, 2017
  30. Evans DGR, Salvador H, Chang VY, Erez A, Voss SD, Schneider KW, et al. : Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1. Clin Cancer Res 23 : e46-e53, 2017 https://doi.org/10.1158/1078-0432.CCR-17-0589
  31. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. : Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44 : 81-88, 2006 https://doi.org/10.1136/jmg.2006.045906
  32. Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, et al. : Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 14 : 790-797, 2012 https://doi.org/10.1093/neuonc/nos076
  33. Girardstein-Boccara L, Mari V, Met-Domestici M, Burel-Vandenbos F, Berthet P, Paquis P, et al. : Gliomas and BRCA genes mutations: fortuitous association or imputability? Bull Cancer 101 : 795-802, 2014
  34. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, et al. : Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27 : 1250-1256, 2009 https://doi.org/10.1200/JCO.2008.16.6959
  35. Goudie C, Coltin H, Witkowski L, Mourad S, Malkin D, Foulkes WD : The McGill Interactive Pediatric OncoGenetic Guidelines: an approach to identifying pediatric oncology patients most likely to benefit from a genetic evaluation. Pediatr Blood Cancer 64 : e26441, 2017 https://doi.org/10.1002/pbc.26441
  36. Gozali AE, Britt B, Shane L, Gonzalez I, Gilles F, McComb JG, et al. : Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010. Pediatr Blood Cancer 58 : 905-909, 2012 https://doi.org/10.1002/pbc.23349
  37. Grill J, Laithier V, Rodriguez D, Raquin MA, Pierre-Kahn A, Kalifa C : When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr 159 : 692-696, 2000 https://doi.org/10.1007/s004310000531
  38. Guillamo JS, Creange A, Kalifa C, Grill J, Rodriguez D, Doz F, et al. : Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 126(Pt 1) : 152-160, 2003 https://doi.org/10.1093/brain/awg016
  39. Gutmann DH, James CD, Poyhonen M, Louis DN, Ferner R, Guha A, et al. : Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology 61 : 1397-1400, 2003 https://doi.org/10.1212/WNL.61.10.1397
  40. Hakan T, Aker FV : Case report on a patient with neurofibromatosis type 1 and a frontal cystic glioblastoma. Neurol Neurochir Pol 42 : 362-365, 2008
  41. Hanahan D, Weinberg RA : Hallmarks of cancer: the next generation. Cell 144 : 646-674, 2011 https://doi.org/10.1016/j.cell.2011.02.013
  42. Henry E, Villalobos V, Million L, Jensen KC, West R, Ganjoo K, et al. : Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Canc Netw 10 : 939-942, 2012 https://doi.org/10.6004/jnccn.2012.0097
  43. Hersh JH; American Academy of Pediatrics Committee on Genetics : Health supervision for children with neurofibromatosis. Pediatrics 121 : 633-642, 2008 https://doi.org/10.1542/peds.2007-3364
  44. Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, et al. : Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 5 : 104, 2010 https://doi.org/10.1186/1748-717X-5-104
  45. Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, et al. : Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol 19 : 1047-1057, 2017 https://doi.org/10.1093/neuonc/nox026
  46. Huttner AJ, Kieran MW, Yao X, Cruz L, Ladner J, Quayle K, et al. : Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer 54 : 890-896, 2010
  47. Jalali A, Amirian ES, Bainbridge MN, Armstrong GN, Liu Y, Tsavachidis S, et al. : Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene consortium. Sci Rep 5 : 8278, 2015 https://doi.org/10.1038/srep08278
  48. Jett K, Friedman JM : Clinical and genetic aspects of neurofibromatosis 1. Genet Med 12 : 1-11, 2010
  49. Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, et al. : Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov 6 : 1230-1236, 2016 https://doi.org/10.1158/2159-8290.CD-16-0575
  50. Kandoth C, Mclellan MD, Vandin F, Ye K, Niu B, Lu C, et al. : Mutational landscape and significance across 12 major cancer types. Nature 502 : 333-339, 2013 https://doi.org/10.1038/nature12634
  51. Kaufman DK, Kimmel DW, Parisi JE, Michels VV : A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma. Neurology 43 : 1728-1731, 1993 https://doi.org/10.1212/WNL.43.9.1728
  52. Khatua S, Gutmann DH, Packer RJ : Neurofibromatosis type 1 and optic pathway glioma: molecular interplay and therapeutic insights. Pediatr Blood Cancer 65 : e26838, 2017
  53. King A, Listernick R, Charrow J, Piersall L, Gutmann DH : Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet 122A : 95-99, 2003 https://doi.org/10.1002/ajmg.a.20211
  54. Kinsella TJ : Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res 15 : 1853-1859, 2009 https://doi.org/10.1158/1078-0432.CCR-08-1307
  55. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H : Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150 : 1-13, 1997
  56. Knapke S, Nagarajan R, Correll J, Kent D, Burns K : Hereditary cancer risk assessment in a pediatric oncology follow-up clinic. Pediatr Blood Cancer 58 : 85-89, 2012 https://doi.org/10.1002/pbc.23283
  57. Kratz CP, Achatz MI, Brugieres L, Frebourg T, Garber JE, Greer MC, et al. : Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res 23 : e38-e45, 2017 https://doi.org/10.1158/1078-0432.CCR-17-0408
  58. Kyritsis AP, Bondy ML, Rao JS, Sioka C : Inherited predisposition to glioma. Neuro Oncol 12 : 104-113, 2010 https://doi.org/10.1093/neuonc/nop011
  59. Lalloo F, Varley J, Ellis D, Moran A, O'Dair L, Pharoah P, et al. : Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361 : 1101-1102, 2003 https://doi.org/10.1016/S0140-6736(03)12856-5
  60. Lavoine N, Colas C, Muleris M, Bodo S, Duval A, Entz-Werle N, et al. : Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. J Med Genet 52 : 770-778, 2015 https://doi.org/10.1136/jmedgenet-2015-103299
  61. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. : PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 : 2509-2520, 2015 https://doi.org/10.1056/NEJMoa1500596
  62. Lemery S, Keegan P, Pazdur R : First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med 377 : 1409-1412, 2017 https://doi.org/10.1056/NEJMp1709968
  63. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. : A cancer family syndrome in twenty-four kindreds. Cancer Res 48 : 5358-5362, 1988
  64. Ligtenberg MJL, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, et al. : Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41 : 112-117, 2009 https://doi.org/10.1038/ng.283
  65. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP : Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 96 : 238-242, 2001 https://doi.org/10.1002/ijc.1021
  66. Listernick R, Ferner RE, Liu GT, Gutmann DH : Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 61 : 189-198, 2007 https://doi.org/10.1002/ana.21107
  67. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK : WHO classification of tumours of the central nervous system, ed 4. Lyon : International Agency for Research on Cancer Publications, 2016
  68. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. : The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol 131 : 803-820, 2016 https://doi.org/10.1007/s00401-016-1545-1
  69. Mai P, Malkin D, Garber JE, Schiffman JD Weitzel JN, Strong LC, et al. : Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet 205 : 479-487, 2012 https://doi.org/10.1016/j.cancergen.2012.06.008
  70. Malkin D : Li-Fraumeni syndrome. Genes Cancer 2 : 475-484, 2011 https://doi.org/10.1177/1947601911413466
  71. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. : Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 : 1233-1238, 1990 https://doi.org/10.1126/science.1978757
  72. Malmer B, Adatto P, Armstrong G, Barnholtz-Sloan J, Bernstein JL, Claus E, et al. : GLIOGENE an international consortium to understand familial glioma. Cancer Epidemiol Biomarkers Prev 16 : 1730-1734, 2007 https://doi.org/10.1158/1055-9965.EPI-07-0081
  73. McKeever K, Shepherd CW, Crawford H, Morrison PJ : An epidemiological, clinical and genetic survey of neurofibromatosis type 1 in children under sixteen years of age. Ulster Med J 77 : 160-163, 2008
  74. Menor F, Marti-Bonmati L, Mulas F, Cortina H, Olague R : Imaging considerations of central nervous system manifestations in pediatric patients with neurofibromatosis type 1. Pediatr Radiol 21 : 389-394, 1991 https://doi.org/10.1007/BF02026665
  75. Miaux Y, Guermazi A, Cornu P, Mokhtari K, Singer B, Chiras J, et al. : Highintensity lesion on T1-weighted MR images in neurofibromatosis type 1: a case of premalignant lesion. Acta Neurochir (Wien) 139 : 1085-1087, 1997 https://doi.org/10.1007/BF01411565
  76. Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, et al. : Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA 314 : 913-925, 2015 https://doi.org/10.1001/jama.2015.10080
  77. Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, et al. : Hypermutated tumours in the era of immunotherapy: the paradigm of personalised medicine. Eur J Cancer 84 : 290-303, 2017 https://doi.org/10.1016/j.ejca.2017.07.026
  78. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, et al. : Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63 : 6643-6650, 2003
  79. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. : An integrated genomic analysis of human glioblastoma multiforme. Science 321 : 1807-1812, 2008 https://doi.org/10.1126/science.1164382
  80. Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, et al. : Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol 2 : 616-624, 2016 https://doi.org/10.1001/jamaoncol.2015.5699
  81. Patil S, Chamberlain RS : Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist 17 : 101-116, 2012 https://doi.org/10.1634/theoncologist.2010-0181
  82. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. : Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28 : 3061-3068, 2010 https://doi.org/10.1200/JCO.2009.26.7252
  83. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, et al. : Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346 : 420-427, 2002 https://doi.org/10.1056/NEJMoa012224
  84. Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, et al. : A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10 : 55-62, 2001 https://doi.org/10.1093/hmg/10.1.55
  85. Ranger A, Szymczak A, Hammond RR, Zelcer S : Pediatric thalamic glioblastoma associated with Ollier disease (multiple enchondromatosis): a rare case of concurrence. J Neurosurg Pediatr 4 : 363-367, 2009 https://doi.org/10.3171/2009.5.PEDS08422
  86. Rednam SP, Erez A, Druker H, Janeway KA, Kamihara J, Kohlmann WK, et al. : Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23 : e68-e75, 2017 https://doi.org/10.1158/1078-0432.CCR-17-0547
  87. Reyes D, Prayson R : Glioblastoma in the setting of tuberous sclerosis. J Clin Neurosci 22 : 907-908, 2015 https://doi.org/10.1016/j.jocn.2014.12.001
  88. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. : Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 : 124-128, 2015 https://doi.org/10.1126/science.aaa1348
  89. Rosenfeld A, Listernick R, Charrow J, Goldman S : Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst 26 : 663-667, 2010 https://doi.org/10.1007/s00381-009-1024-2
  90. Rosser T, Packer RJ : Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol 17 : 630-637; discussion 646-651, 2002 https://doi.org/10.1177/088307380201700815
  91. Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, et al. : Regression of chemotherapy-resistant polymerase $\epsilon$ (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res 22 : 5682-5687, 2016 https://doi.org/10.1158/1078-0432.CCR-16-1031
  92. Saya S, Killick E, Thomas S, Taylor N, Bancroft EK, Rothwell J, et al. : Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. Fam Cancer 16 : 433-440, 2017 https://doi.org/10.1007/s10689-017-9965-1
  93. Scheffzek K, Ahmadian MR, Wiesmuller L, Kabsch W, Stege P, Schmitz F, et al. : Structural analysis of the GAP-related domain from neurofibromin and its implications. EMBO J 17 : 4313-4327, 1998 https://doi.org/10.1093/emboj/17.15.4313
  94. Schneider K, Zelley K, Nichols KE, Garber J : Li-Fraumeni syndrome in Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (eds) : $GeneReviews^{(R)}$. Seattle : University of Washington, 1993
  95. Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, et al. : Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 24 : 2570-2575, 2006 https://doi.org/10.1200/JCO.2005.03.8349
  96. Sherborne AL, Lavergne V, Yu K, Lee L, Davidson PR, Mazor T, et al. : Somatic and germline TP53 alterations in second malignant neoplasms from pediatric cancer survivors. Clin Cancer Res 23 : 1852-1861, 2017 https://doi.org/10.1158/1078-0432.CCR-16-0610
  97. Shete S, Lau CC, Houlston RS, Claus EB, Barnholtz-Sloan J, Lai R, et al. : Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the gliogene consortium. Cancer Res 71 : 7568-7575, 2011 https://doi.org/10.1158/0008-5472.CAN-11-0013
  98. Shibahara I, Sonoda Y, Suzuki H, Mayama A, Kanamori M, Saito R, et al. : Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations. Brain Tumor Pathol 1 : 10-18, 2018
  99. Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, et al. : Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet 47 : 257-262, 2015 https://doi.org/10.1038/ng.3202
  100. Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, et al. : Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 28 : 1345-1350, 2010 https://doi.org/10.1200/JCO.2009.23.5952
  101. Tabori U, Hansford JR, Achatz MI, Kratz CP, Plon SE, Frebourg T, et al. : Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood. Clin Cancer Res 23 : e32-e37, 2017 https://doi.org/10.1158/1078-0432.CCR-17-0574
  102. Tabori U, Laberge AM, Ellezam B, Carret AS : Cancer Predisposition in Children with Brain Tumors : Pediatric Neuro-oncology. New York : Springer New York, 2015, pp69-89
  103. Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, et al. : TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 28 : 1995-2001, 2010 https://doi.org/10.1200/JCO.2009.26.8169
  104. Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, et al. : 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27 : e108-e109; author reply e110, 2009 https://doi.org/10.1200/JCO.2009.22.7967
  105. Unger PD, Taff ML, Song S, Schwartz IS : Sudden death in a patient with Von Recklinghausen's neurofibromatosis. Am J Forensic Med Pathol 5 : 175-179, 1984 https://doi.org/10.1097/00000433-198406000-00014
  106. Uyttebroeck A, Legius E, Brock P, Van de Cassey W, Casaer P, Casteels-Van Daele M : Consecutive glioblastoma and B cell non-Hodgkin's lymphoma in a young child with von Recklinghausen's neurofibromatosis. Med Pediatr Oncol 24 : 46-49, 1995 https://doi.org/10.1002/mpo.2950240110
  107. Varan A, Sen H, Aydin B, Yalcin B, Kutluk T, Akyuz C : Neurofibromatosis type 1 and malignancy in childhood. Clin Genet 89 : 341-345, 2016 https://doi.org/10.1111/cge.12625
  108. Villani A, Malkin D, Tabori U : Syndromes predisposing to pediatric central nervous system tumors: lessons learned and new promises. Curr Neurol Neurosci Rep 12 : 153-164, 2012 https://doi.org/10.1007/s11910-011-0244-5
  109. Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, et al. : Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 17 : 1295-1305, 2016 https://doi.org/10.1016/S1470-2045(16)30249-2
  110. Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Galindo C, Zambetti GP, et al. : Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. J Clin Oncol 33 : 602-609, 2015 https://doi.org/10.1200/JCO.2013.52.6863
  111. Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H : Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol 117 : 653-656, 2009 https://doi.org/10.1007/s00401-009-0528-x
  112. Wimmer K, Etzler J : Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet 124 : 105-122, 2008 https://doi.org/10.1007/s00439-008-0542-4
  113. Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, et al. : Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium "Care for CMMRD" (C4CMMRD). J Med Genet 51 : 355-365, 2014 https://doi.org/10.1136/jmedgenet-2014-102284
  114. Wimmer K, Rosenbaum T, Messiaen L : Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. Clin Genet 91 : 507-519, 2017 https://doi.org/10.1111/cge.12904
  115. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. : Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 373 : 2336-2346, 2015 https://doi.org/10.1056/NEJMoa1508054
  116. Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, et al. : Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 31 : 2927-35, 2013 https://doi.org/10.1200/JCO.2012.48.5052

Cited by

  1. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study vol.10, pp.None, 2020, https://doi.org/10.3389/fonc.2020.00795
  2. Cancer Predisposition Syndromes and Medulloblastoma in the Molecular Era vol.10, pp.None, 2020, https://doi.org/10.3389/fonc.2020.566822
  3. Cancer Predisposition Syndromes Associated With Pediatric High-Grade Gliomas vol.8, pp.None, 2018, https://doi.org/10.3389/fped.2020.561487
  4. Neuroimaging Findings in Children with Constitutional Mismatch Repair Deficiency Syndrome vol.41, pp.5, 2020, https://doi.org/10.3174/ajnr.a6512
  5. Parental attitudes regarding the need for genetic services in a pediatric brain tumor survivorship program vol.30, pp.2, 2021, https://doi.org/10.1002/jgc4.1339
  6. A Unique Case of Bilateral Thalamic High-Grade Glioma in a Pediatric Patient with LI-Fraumeni Syndrome: Case Presentation and Review of the Literature vol.13, pp.2, 2021, https://doi.org/10.3390/neurolint13020017